13.6% Average Loss With Oral Semaglutide at 64 Weeks
OASIS 4 tested once-daily oral semaglutide 25 mg in adults without diabetes. The reported 64-week average describes that dose, population, lifestyle intervention, and trial follow-up—not an outcome a provider can promise or an assurance that an online program offers the studied regimen.
At week 64, estimated mean body-weight change was −13.6% with oral semaglutide 25 mg and −2.2% with placebo.
The estimated between-group difference was −11.4 percentage points. Oral semaglutide was superior on the study's categorical weight-loss thresholds; gastrointestinal adverse events occurred in 74.0% of participants receiving semaglutide and 42.2% receiving placebo.
Turn the study result into a better program comparison
If this oral-semaglutide result prompts you to compare GLP-1 programs, separate the study from the service questions it did not answer: available medication forms, clinician access, product status, public price terms, follow-up, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Study details
- Population
- 307 adults without diabetes who had obesity, or overweight plus at least one obesity-related complication
- Follow-up
- 64-week treatment period; 71 weeks including post-treatment follow-up
- Treatment comparison
- Once-daily oral semaglutide 25 mg compared with matching placebo, with lifestyle intervention in both groups
- Study design
- Phase 3, multicenter, double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
This study does not determine whether oral semaglutide is appropriate for an individual, which product or dose a provider can prescribe, or what insurance will cover. It was not a telehealth comparison. Current product labeling, tablet availability, dose progression, and treatment suitability require a licensed clinician and current prescribing information.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The trial used a placebo comparator, not injectable semaglutide or another active obesity medicine, so it cannot provide head-to-head comparative effectiveness.
- The 64-week treatment period and 7-week post-treatment observation do not establish longer-term durability or outcomes after stopping treatment.
- Participants did not have diabetes, so the findings do not directly answer outcomes in people with type 2 diabetes.
- The 307-person sample was not designed to precisely characterize uncommon adverse events or clinical-event outcomes.
- Novo Nordisk funded the study and funded medical-writing support, as disclosed in the paper.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine